AT-121
Legal status
Legal status
  • Investigational
Identifiers
  • 3-oxo-1'-(4-propan-2-ylcyclohexyl)-2-[2-(sulfamoylamino)ethyl]spiro[1H-isoquinoline-4,4'-piperidine]
CAS Number
PubChem CID
Chemical and physical data
FormulaC24H38N4O3S
Molar mass462.65 g·mol−1
3D model (JSmol)
  • CC(C)[C@H]1CC[C@H](CC1)N1CCC2(CC1)C(=O)N(CCNS(N)(=O)=O)CC1=CC=CC=C21

AT-121 is an experimental analgesic. It was designed to be bifunctional, acting as an agonist at both the μ-opioid receptor and the nociceptin receptor.[1] The interaction with the nociceptin receptor is expected to block the abuse and dependence-related side effects that are typical of opioids.[2] A study in nonhuman primates found that AT-121 has morphine-like analgesic effects, but suppressed the addictive effects.[1][3]

See also

References

  1. 1 2 Ding H, Kiguchi N, Yasuda D, Daga PR, Polgar WE, Lu JJ, et al. (August 2018). "A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates". Science Translational Medicine. 10 (456): eaar3483. doi:10.1126/scitranslmed.aar3483. PMC 6295194. PMID 30158150.
  2. ↑ "Scientists take big step toward finding non-addictive painkiller". Science Daily. August 29, 2018.
  3. ↑ "Study: Non-addictive painkiller is safe, effective in animals". UPI. August 30, 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.